Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

VTGN vs LCTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LCTX Captures Overall Composite Edge (58.9 HOLD vs 42.3 HOLD), While VTGN Leads 3–2 on Growth & Valuation Pillars

LCTX Overall Winner 6-Pillar Tally: VTGN 3 – 2 LCTX (1 Tie) Matrix Metrics: VTGN 1 – 9 LCTX

As of Nov 19, 2026, Lineage Cell Therapeutics, Inc. (LCTX) captures the overall head-to-head institutional edge over Vistagen Therapeutics, Inc. (VTGN) on higher Unified Composite conviction (58.9/100 HOLD vs. 42.3/100 HOLD) after splitting the core matrix 9–1 (led by Valuation Multiples, Profitability & Quality), while VTGN wins 3–2 across the 6-pillar growth and valuation breakdown. VTGN trades at $0.19 (N/M Forward P/E, -2543.1% operating margin) versus LCTX at $0.82 (30.7x Forward P/E, -280.3% operating margin).

  • Growth vs. Quality Trade-Off: LCTX earns the overall head-to-head edge with a stronger Unified Composite Score (58.9/100 HOLD vs. VTGN 42.3/100 HOLD) and 1.36β · 79% Vol risk profile, whereas VTGN leads top-line expansion (-46.5% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VTGN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.0); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VTGN vs LCTX
VTGN NASDAQ
Vistagen Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.19
-6.47% 1D
Market Cap $9.0M
TTM Revenue $2.4M
Forward P/E N/M
Beta / 30D Vol 1.23β · 80% Vol
Unified Composite Score
42.3 / 100 HOLD
Tech 20.0 Fund 52.0 Flow 69.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.0 · SMA20: $0.18 · SMA50: $0.22
LCTX NYSE American Head-to-Head Winner
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
TTM Revenue $11M
Forward P/E 30.7x
Beta / 30D Vol 1.36β · 79% Vol
Unified Composite Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.3%), weak momentum, RSI 37
RSI-14: 37.1 · SMA20: $0.98 · SMA50: $0.98

6-Pillar Scorecard Institutional Category Breakdown (VTGN 3 – 2 LCTX)

Columns: Metric · VTGN · LCTX
1. Valuation Multiples LCTX
Forward P/E N/M 30.7x
Trailing P/E N/M 30.7x
PEG Ratio N/M 10.64x
EV / Revenue N/M 16.3x
2. Growth & Scale VTGN
Revenue Growth (YoY) -46.5% -61.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.4M $11M
Market Cap $9.0M $212.1M
3. Profitability & Quality LCTX
Gross Margin 100.0% -95.0%
Operating Margin -2543.1% -280.3%
Net Profit Margin 0.0% 16.2%
Return on Equity (ROE) -144.9% 4.3%
4. Balance Sheet & Cash Flow VTGN
Cash Generation (TTM) -$60M EBITDA -$24M
Cash Flow Margin N/A N/A
Net Cash / Leverage $30M Net Cash $35M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VTGN
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 274.8% (71st %ile) 896.2% (100th %ile)
Put/Call OI Skew N/A 1.10x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VTGN (1) vs LCTX (9)
Institutional Metric VTGN LCTX Criterion Row Edge
Market Capitalization
Scale
$9.0M $212.1M Larger Scale LCTX
Trailing P/E Ratio
Valuation
N/M 30.7x Lower Multiple LCTX
Forward P/E Ratio
Valuation
N/M 30.7x Lower Multiple LCTX
Revenue Growth (YoY)
Growth
-46.5% -61.0% Higher Growth VTGN
Operating Margin (TTM)
Profitability
-2543.1% -280.3% Higher Margin LCTX
Net Profit Margin
Profitability
0.0% 16.2% Higher Margin LCTX
Return on Equity (ROE)
Capital Efficiency
-144.9% 4.3% Higher ROE LCTX
52-Week Range Position
Momentum
0% ($0–$5) 4% ($1–$2) Stronger Trend LCTX
Beta / 30D Volatility
Risk Regime
1.23β · 80% Vol 1.36β · 79% Vol Lower Realized Risk LCTX
Unified Institutional Score
Composite Signal
42.3 / 100 (HOLD) 58.9 / 100 (HOLD) Higher Composite LCTX
Trailing 12M Revenue (USD)
Operating Scale
$2.4M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% -95.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 10.64x PEG · 16.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$60M EBITDA ($30M Net Cash) -$24M ($35M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VTGN +10.2 pp
VTGN: -3.62% · LCTX: -13.82%
3M Horizon VTGN +0.55 pp
VTGN: -23.52% · LCTX: -24.07%
6M Horizon LCTX +32.83 pp
VTGN: -70.71% · LCTX: -37.88%
1Y Horizon LCTX +42.3 pp
VTGN: -95.97% · LCTX: -53.67%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VTGN Revenue LCTX Revenue VTGN Op. Margin LCTX Op. Margin Margin Leader
FY2019 N/A $0M N/A -1106.0% LCTX
FY2020 N/A $0M N/A -1448.4% LCTX
FY2021 $0M $0M -1646.1% -1133.6% LCTX
FY2022 $0M $10M -4308.3% -153.2% LCTX
FY2023 N/A $10M N/A -276.5% LCTX
FY2024 $0M $10M -3103.5% -226.1% LCTX
FY2025 $0M $10M -11517.1% -251.6% LCTX
FY2026 $0M N/A -5683.7% N/A VTGN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VTGN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 274.8%
IV Percentile 71st %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VTGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LCTX BREAKDOWN
6d in phase · OBV DISTRIBUTION
Current IV 896.2%
IV Percentile 100th %ile
Put/Call OI Skew 1.10x (Balanced)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VTGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.0M market capitalization and -2543.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LCTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $212.1M market capitalization and -280.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VTGN vs LCTX Key Questions & Quantitative Answers

As of Nov 19, 2026, Lineage Cell Therapeutics, Inc. (LCTX) captures the overall head-to-head institutional edge over Vistagen Therapeutics, Inc. (VTGN) on higher Unified Composite conviction (58.9/100 HOLD vs. 42.3/100 HOLD) after splitting the core matrix 9–1 (led by Valuation Multiples, Profitability & Quality), while VTGN wins 3–2 across the 6-pillar growth and valuation breakdown. VTGN trades at $0.19 (N/M Forward P/E, -2543.1% operating margin) versus LCTX at $0.82 (30.7x Forward P/E, -280.3% operating margin). Growth vs. Quality Trade-Off: LCTX earns the overall head-to-head edge with a stronger Unified Composite Score (58.9/100 HOLD vs. VTGN 42.3/100 HOLD) and 1.36β · 79% Vol risk profile, whereas VTGN leads top-line expansion (-46.5% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VTGN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.0); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VTGN leads the Growth & Scale pillar: VTGN posts -46.5% YoY revenue growth and +0.0% YoY earnings growth on $2.4M TTM revenue (100.0% gross margin, -2543.1% operating margin), compared with LCTX at -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), VTGN cumulative revenue shifted N/A while LCTX shifted +0.0%. In operating R&D and SG&A reinvestment, VTGN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LCTX.

LCTX screens cheaper on headline valuation multiples. VTGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 16.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTGN (-144.9% ROE) versus LCTX (4.3% ROE) capital efficiency.

In options market volatility and institutional positioning, VTGN carries 274.8% implied volatility (71st %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.23β · 80% Vol realized risk). By comparison, LCTX carries 896.2% implied volatility (100th %ile, Extreme (>80th %ile)), a 1.10x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.36β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.